Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a report issued on Wednesday, MarketBeat.com reports. They presently have a $115.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 12.57% from the company’s previous close.

Johnson & Johnson (NYSE:JNJ) traded up 0.97% during midday trading on Wednesday, hitting $102.16. The stock had a trading volume of 19,330,465 shares. The company’s 50-day moving average price is $100.68 and its 200 day moving average price is $98.63. The company has a market capitalization of $282.67 billion and a PE ratio of 19.60. Johnson & Johnson has a 52 week low of $81.79 and a 52 week high of $105.49.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 26th. The company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.02. During the same period in the prior year, the business earned $1.27 earnings per share. The company had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.88 billion. The firm’s revenue for the quarter was down 2.4% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post $6.40 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 23rd will be paid a dividend of $0.75 per share. The ex-dividend date is Friday, February 19th. This represents a $3.00 dividend on an annualized basis and a yield of 2.94%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.61.

JNJ has been the subject of a number of other reports. Atlantic Securities assumed coverage on Johnson & Johnson in a report on Friday, December 18th. They set a “neutral” rating and a $95.00 price target for the company. Jefferies Group reiterated a “hold” rating and set a $95.00 price target on shares of Johnson & Johnson in a report on Monday, December 7th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $106.75 price target for the company in a report on Monday, November 30th. Barclays assumed coverage on Johnson & Johnson in a report on Wednesday, December 2nd. They set a “buy” rating for the company. Finally, Credit Suisse reiterated a “neutral” rating and set a $110.00 price target (up from $109.00) on shares of Johnson & Johnson in a report on Wednesday, November 4th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $107.83.

A number of institutional investors recently added to or reduced their stakes in the stock. Lowe FS increased its position in Johnson & Johnson by 15.2% in the third quarter. Lowe FS now owns 379 shares of the company’s stock worth $35,000 after buying an additional 50 shares during the period. Jennison Associates bought a new position in Johnson & Johnson during the third quarter worth about $3,264,000. Ken Stern & Associates increased its position in Johnson & Johnson by 10.0% in the third quarter. Ken Stern & Associates now owns 9,050 shares of the company’s stock worth $845,000 after buying an additional 826 shares during the period. Baker Avenue Asset Management increased its position in Johnson & Johnson by 4.0% in the third quarter. Baker Avenue Asset Management now owns 48,470 shares of the company’s stock worth $4,525,000 after buying an additional 1,871 shares during the period. Finally, Palo Capital increased its position in Johnson & Johnson by 20.0% in the third quarter. Palo Capital now owns 33,321 shares of the company’s stock worth $3,111,000 after buying an additional 5,560 shares during the period.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

12 Month Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.